



# **Revisões sistemáticas e metanálise**

**Prof. Fredi Alexander Diaz Quijano**  
**Departamento Epidemiologia**

# Revisões sistemáticas

Identificação de estudos já concluídos que abordaram uma questão de pesquisa

e

avaliação dos resultados para se chegar a conclusões sobre um corpo de conhecimentos.

# Revisões sistemáticas

Usam uma abordagem bem-definida e uniforme para:

- Identificar todos os estudos relevantes.
- Mostrar os resultados dos estudos elegíveis.
- Quando apropriado, calcular estimativa-sumário.

# Metanálise

Métodos estatísticos usados em Revisões sistemáticas para:

- Cálculo das estimativas-sumário de efeito e variância.
- Avaliar a heterogeneidade.
- Avaliar o viés de publicação.

# Elementos da Revisão Sistemática

1. Questão de pesquisa clara
2. Identificação abrangente e não-enviesada dos estudos
3. Definição de critérios de inclusão e exclusão
4. Extração uniforme e sem viés das características e dos achados de cada estudo
5. Apresentação clara e uniforme dos dados de estudos individuais.

## Questão de pesquisa clara

Em indivíduos admitidos em uma UTI com angina instável, o tratamento com aspirina mais heparina endovenosa, reduz o risco de infarto e morte durante hospitalização, quando comparado ao tratamento apenas com aspirina?

## Questão de pesquisa clara

População

**Em indivíduos admitidos em uma UTI com angina instável,**

Intervenção

**o tratamento com aspirina mais heparina endovenosa,**

Desfecho

**reduz o risco de infarto e morte durante hospitalização,**

Grupo de Comparação

**quando comparado ao tratamento apenas com aspirina?**

# Identificação dos estudos

## Termos de Busca:

*unstable angina AND aspirin AND intravenous  
heparin AND ((heart attack) or (death))*

As buscas devem incluir várias bases eletrônicas: MEDLINE, EMBASE, Crochrane, etc



# Identificação dos estudos

pubmed.ncbi.nlm.nih.gov/?term=unstable+angina+AND+aspirin+AND+intravenous+heparin+AND+%28heart+attack%29+or+%28death%29...



National Library of Medicine  
National Center for Biotechnology Information

Log in

PubMed.gov

unstable angina AND aspirin AND intravenous heparin AND ((heart attack) o

Search

Advanced Create alert Create RSS

User Guide

Save

Email

Send to


Sorted by: Most recent

Display options

MY NCBI FILTERS

138 results

RESULTS BY YEAR



TEXT AVAILABILITY

- Abstract
- Free full text
- Full text

ARTICLE ATTRIBUTE

- Associated data

ARTICLE TYPE

- Books and Documents
- Clinical Trial
- Meta-Analysis

**New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.**

1 Davis EM, Packard KA, Knezevich JT, Campbell JA.

Pharmacotherapy. 2011 Oct;31(10):975-1016. doi: 10.1592/phco.31.10.975.

Share PMID: 21950643 Review.

Abstract Thrombosis is an underlying cause of many cardiovascular disorders, and generation of thrombi in the arterial circulation can lead to **unstable angina**, **myocardial infarction**, or ischemic stroke. Antithrombotic therapy is widely used, with prove ...

**Non ST-elevation acute coronary syndrome.**

2 Sarkees ML, Bavry AA.

Cite BMJ Clin Evid. 2010 Nov 15;2010:0209.

PMID: 21406132 [Free PMC article.](#) Review.

Share INTRODUCTION: Non ST-elevation acute coronary syndrome (NSTEMI, here defined as **unstable angina** and non ST-elevation MI) is characterised by episodes of chest pain at rest or with minimal exertion, which increase in frequency or severity, often with dynamic ECG ch ...

**Acute coronary syndrome (**unstable angina** and non-ST elevation MI).**

3 Sarkees ML, Bavry AA.

Cite BMJ Clin Evid. 2009 Jan 13;2009:0209.

PMID: 19445778 [Free PMC article.](#) Review.

Share INTRODUCTION: In people with acute coronary syndrome (ACS) the incidence of serious adverse outcomes (such as **death**, acute **myocardial infarction** [MI], or refractory **angina** requiring emergency

# Critérios de inclusão e exclusão dos estudos

Procuram garantir a validade da revisão. Se possível, estabelecidos *a priori*

Tipicamente, referem-se a:

- População
- Doença ou condição de interesse
- Intervenção
- Grupos controle
- Características do desenho (cegamento, perdas máximas, duração do seguimento).

# Elementos da Revisão Sistemática

1. Questão de pesquisa clara
2. Identificação abrangente e não-enviesada dos estudos
3. Definição de critérios de inclusão e exclusão
- 4. Extração uniforme e sem viés das características e dos achados de cada estudo**
5. Apresentação clara e uniforme dos dados de estudos individuais.

# Elementos da Revisão Sistemática


1. Questão de pesquisa clara
2. Identificação abrangente e não-enviesada dos estudos
3. Definição de critérios de inclusão e exclusão
4. Extração uniforme e sem viés das características e dos achados de cada estudo
5. **Apresentação clara e uniforme dos dados de estudos individuais.**

# Predictores de sangrado espontáneo en dengue: una revisión sistemática de la literatura.

Fredi Alexander Díaz-Quijano.

combinación de palabras:

Dengue AND (patients OR children OR adult) AND (bleeding OR hemorrhage OR hemorrhages OR metrorrhagia OR hematuria OR hematemesis OR epistaxis OR gingival OR melena OR tourniquet OR Petechiae OR purpura OR Hematochesia) AND (clinical OR manifestation OR laboratory OR test OR platelet OR coagulation OR biochemical OR prognosis OR predict\* OR associat\* OR relation\* OR risk).



Guidelines and Guidance

# Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

**David Moher<sup>1,2\*</sup>, Alessandro Liberati<sup>3,4</sup>, Jennifer Tetzlaff<sup>1</sup>, Douglas G. Altman<sup>5</sup>, The PRISMA Group<sup>¶</sup>**

**1** Ottawa Methods Centre, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, **2** Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada, **3** Università di Modena e Reggio Emilia, Modena, Italy, **4** Centro Cochrane Italiano, Istituto Ricerche Farmacologiche Mario Negri, Milan, Italy, **5** Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom

<https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1000097&type=printable>

Section/Topic # Checklist Item

<b>TITLE</b>		
Title	1	Identify the report as a systematic review, meta-analysis, or both.
<b>ABSTRACT</b>		
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
<b>INTRODUCTION</b>		
Rationale	3	Describe the rationale for the review in the context of what is already known.
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
<b>METHODS</b>		
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
<b>RESULTS</b>		
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome-level assessment (see Item 12).
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot.

Erica Aranha Suzumura  
Mabel Figueiró  
Karina Normilio-Silva  
Lígia Laranjeira  
Claudia Oliveira  
Anna Maria Buehler  
Diogo Bugano  
Marcelo Britto Passos Amato  
Carlos Roberto Ribeiro Carvalho  
Otavio Berwanger  
Alexandre Biasi Cavalcanti


# Effects of alveolar recruitment maneuvers on clinical outcomes in patients with acute respiratory distress syndrome: a systematic review and meta-analysis







**PEEP ALTA**

**ALVÉOLO**



First author/year	Eligibility	Group	Number of patients	Type of ARM	Method to adjust <a href="#">PEEP</a>
Lim/2003 [27]	PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 200 mmHg for <7 days	ARM	20	Stepwise increase of <a href="#">PEEP</a> (from 10 to 30 cmH <sub>2</sub> O) with a ...	<a href="#">PEEP</a> set at 15 cmH <sub>2</sub> O for all patients
		Control	8	NA	Similar to experimental group
Park/2003 [28]	PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 200 mmHg for <2 days	ARM	11	CPAP 30–35 cmH <sub>2</sub> O for 30 s, twice daily	<a href="#">PEEP</a> was set before ARM performing stepwise increase from 8 to 15 cmH <sub>2</sub> O (in increments of 2 cmH <sub>2</sub> O) and set based ...
		Control	6	NA	Similar to experimental group
Long/2006 [29]	PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 200 mmHg for <24 h	ARM	16	Not stated	<a href="#">PEEP</a> was set daily based on P–V curve variation
		Control	14	NA	According to ARDSNet high <a href="#">PEEP</a> table <sup>b</sup>
Wang/2007 [30]	PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 200 mmHg	ARM	14	CPAP 35 cmH <sub>2</sub> O for 35 s after suctioning	According to ARDSNet table <sup>c</sup>
		Control	14	NA	According to ARDSNet table <sup>c</sup>


**Effect on in-hospital mortality****Effect on barotrauma****Effect on severe hypoxemia requiring rescue therapies**

# Elementos da Revisão Sistemática

(Metanálise)

6. Avaliação da heterogeneidade dos achados dos estudos individuais.
7. Quando apropriado, cálculo de estimativa-sumário do efeito e do Intervalo de confiança.
8. Avaliação do potencial viés de publicação.
9. Análise de subgrupo e de sensibilidade.


# Avaliação do heterogeneidade dos estudos



**FIGURA 2.** Apresentação gráfica de ensaios clínicos randomizados (ECR) homogêneos (a esquerda) y heterogêneos (a direita). RR = riesgo relativo.

# Estimativa sumário e Intervalo de confiança

## Effect on in-hospital mortality



# Estimativa sumário e Intervalo de confiança

Efeito Global (Fixo):

$$\hat{\theta} = \frac{\sum_{i=1}^k w_i \hat{\theta}_i}{\sum_{i=1}^k w_i}$$

$$w_i = \frac{1}{\text{Var}(\hat{\theta}_i)}$$

$$\text{Var}(\hat{\theta}) = \frac{1}{\sum_{i=1}^k w_i}$$



# Estimativa sumário e Intervalo de confiança

Se a medida de efeito é o RR, então,

$$\theta_i = \text{Logaritmo natural do RR}$$

$$\text{Var}(\theta_i) = \frac{1}{a} + \frac{1}{c} - \frac{1}{a+b} - \frac{1}{c+d}$$

	Evento	Nao Evento	
Expostos	a	b	a+b
Não Expostos	c	d	c+d
	a+c	b+d	n



# Estimativa sumário e Intervalo de confiança

Efeito Global (Fixo):

$$\hat{\theta} = \frac{\sum_{i=1}^k w_i \hat{\theta}_i}{\sum_{i=1}^k w_i}$$


$$w_i = \frac{1}{\text{Var}(\hat{\theta}_i)}$$

$$\text{Var}(\hat{\theta}) = \frac{1}{\sum_{i=1}^k w_i}$$

**Effect on in-hospital mortality****Effect on barotrauma****Effect on severe hypoxemia requiring rescue therapies**


# Avaliação do viés de publicação

Gráfico de funil não-enviesado





# Avaliação do viés de publicação




# Elementos da Revisão Sistemática

(Metanálise)

6. Avaliação da heterogeneidade dos achados dos estudos individuais.
7. Quando apropriado, cálculo de estimativa-sumário do efeito e do Intervalo de confiança.
8. Avaliação do potencial viés de publicação.
9. Análise de subgrupos e de sensibilidade.

# Análise de subgrupos





## **Análise de sensibilidade.**

Avaliação da influência de cada um dos estudos nos resultados.

Replicar a meta-análise excluindo em cada passo um dos estudos incluídos na revisão.

Resultados semelhantes em direção, magnitude do efeito e em significância estatística, indicam um resultado robusto.



Este processo pode ser repetido eliminando vários estudos (Ex, aqueles de pior qualidade, não publicado, etc.) para determinar a sua possível influência nos resultados.

# Revisão Sistemática

## Importante:

As **características** e os **achados** de estudos individuais devem ser apresentados claramente, permitindo que o leitor forme opiniões que não dependam das estatísticas sumário.

A maior **limitação** da Revisão Sistemática é que a confiabilidade dos resultados é limitada pela qualidade dos estudos incluídos.

**Effect on in-hospital mortality****Effect on barotrauma**

This Issue

Views 140,603 | Citations 273 | Altmetric 351



PDF



More



Cite



Permissions

Original Investigation | Caring for the Critically Ill Patient

FREE

October 10, 2017

# Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome

## A Randomized Clinical Trial

Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART)

CONTENTS

FIGURES / TABLES

MULTIMEDIA

SUPPLEMENTAL CONTENT

REFERENCES


RELATED

Table 1. Baseline Characteristics of the Patients

Characteristic	Lung Recruitment Maneuver With PEEP Titration Group (n = 501)	Low-PEEP Group (n = 509)
Age, mean (SD), y	51.3 (17.4)	50.6 (17.4)
Women, No. (%)	188 (37.5)	191 (37.5)
SAPS 3 score, mean (SD) <sup>a</sup>	63.5 (18.1)	62.7 (18.1)
No. of nonpulmonary organ failures, median (IQR)	2 (2-3)	2 (2-3)
Septic shock, No. (%)	336 (67.1)	331 (65.0)
Cause of ARDS, No. (%)		
Pulmonary ARDS	313 (62.5)	313 (61.5)
Pneumonia	280 (55.9)	276 (54.2)
Gastric aspiration	26 (5.2)	32 (6.3)

PDF

Help




No. at risk

Lung recruitment and titrated PEEP	501	397	340	303	276	254	233	225
Low PEEP	509	423	378	343	312	286	264	260

<https://jamanetwork.com/journals/jama/fullarticle/2654894>

At 28 days, 277 of 501 patients (55.3%) in the experimental group and 251 of 509 patients (49.3%) in the control group had died (HR: 1.20; 95%CI: 1.01 to 1.42;  $P = .041$ )

Subgroup	No. of Deaths/Total No. (%)		Hazard Ratio (95% CI)
	Lung Recruitment and Titrated PEEP (n= 501)	Low PEEP (n=509)	
<b>PaO<sub>2</sub>: FIO<sub>2</sub></b>			
≤100 mm Hg	117/197 (59.4)	120/214 (56.1)	1.09 (0.82-1.46)
>100 mm Hg	160/304 (52.6)	131/295 (44.4)	1.30 (1.00-1.69)
<b>Simplified Acute Physiology Score 3</b>			
<50	47/117 (40.2)	48/119 (40.3)	1.03 (0.65-1.64)
≥50	230/384 (59.9)	203/390 (52.1)	1.24 (1.00-1.54)
<b>Type of ARDS</b>			
Extrapulmonary	98/188 (52.1)	102/196 (52)	1.02 (0.74-1.40)
Pulmonary	179/313 (57.2)	149/313 (47.6)	1.32 (1.03-1.69)
<b>Duration of ARDS at randomization, h</b>			
≤36	214/388 (55.2)	196/405 (48.4)	1.22 (0.98-1.52)
>36 to <72	63/113 (55.8)	55/104 (52.9)	1.11 (0.73-1.67)
<b>Position 1 h after randomization</b>			
Supine (dorsal decubitus) or lateral decubitus	153/274 (55.8)	132/273 (48.4)	1.26 (0.96-1.64)
Prone	19/31 (61.3)	20/30 (66.7)	0.82 (0.40-1.67)
<b>Duration of mechanical ventilation before randomization, d</b>			
0-2	160/297 (53.9)	152/320 (47.5)	1.20 (0.92-1.56)
3-4	54/88 (61.4)	41/77 (53.2)	1.26 (0.77-2.07)
≥5	63/116 (54.3)	58/112 (51.8)	1.12 (0.73-1.71)
<b>Protocol modification</b>			
Before	151/273 (55.3)	138/280 (49.3)	1.21 (0.93-1.57)
After	126/228 (55.3)	113/229 (49.3)	1.18 (0.88-1.58)



<https://jamanetwork.com/journals/jama/fullarticle/2654894>

## Links de cursos:

- <https://www.coursera.org/learn/revisao-sistematica>
- <https://www.coursera.org/learn/systematic-review>

## REFERENCIAS

1. Grady D & Hearst N. **Usando Bases de Datos Existentes**. Em: Hulley SB, Cummings SR, Browner WS, Grady DG & Newman TB. **Delineando a Pesquisa Clínica – Uma abordagem epidemiológica**. 3ª Ed. 2008. Cap. 13. p. **231-240**.
2. Pabalan N, Jarjanazi H, Steiner T S. **Meta-analysis in microbiology**. Indian J Med Microbiol 2014;32:229-35
3. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). **Preferred Reporting Items for Systematic Reviews and MetaAnalyses: The PRISMA Statement**. PLoS Med 6(7): e1000097. doi:10.1371/ journal.pmed.1000097
4. Díaz-Quijano FA. **Predictores de sangrado espontáneo en dengue: una revisión sistemática de la literatura**. Invest. clín. 2008; 49( 1 ): 111-122. Disponible en: [http://ve.scielo.org/scielo.php?script=sci\\_arttext&pid=S0535-51332008000100012&lng=es](http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0535-51332008000100012&lng=es).
5. Suzumura EA, Figueiró M, Normilio-Silva K, Laranjeira L, Oliveira C, Buehler AM, Bugano D, Passos Amato MB, Ribeiro Carvalho CR, Berwanger O, Cavalcanti AB. **Effects of alveolar recruitment maneuvers on clinical outcomes in patients with acute respiratory distress syndrome: a systematic review and meta-analysis**. Intensive Care Med. 2014 Sep;40(9):1227-40. doi: 10.1007/s00134-014-3413-6. Epub 2014 Aug 6. PMID: 25097070.
6. Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators. **Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial**. JAMA. 2017;318(14):1335–1345. doi:10.1001/jama.2017.14171